Lido Advisors LLC increased its stake in shares of Allergan (NYSE:AGN) by 53.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 3,364 shares of the company’s stock after purchasing an additional 1,170 shares during the period. Lido Advisors LLC’s holdings in Allergan were worth $566,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the stock. Avestar Capital LLC purchased a new position in Allergan in the 4th quarter valued at approximately $113,000. Focused Wealth Management Inc boosted its position in Allergan by 4,444.4% in the 4th quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after buying an additional 800 shares during the period. Field & Main Bank purchased a new position in Allergan in the 4th quarter valued at approximately $155,000. Captrust Financial Advisors purchased a new position in Allergan in the 4th quarter valued at approximately $175,000. Finally, Bfsg LLC purchased a new position in Allergan in the 1st quarter valued at approximately $206,000. 79.57% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:AGN opened at $155.95 on Thursday. Allergan has a 12 month low of $142.81 and a 12 month high of $256.80. The company has a current ratio of 1.10, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The firm has a market cap of $52.55 billion, a P/E ratio of 9.54, a P/E/G ratio of 1.11 and a beta of 1.17.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 15th. Investors of record on Friday, May 18th will be paid a dividend of $0.72 per share. The ex-dividend date is Thursday, May 17th. This represents a $2.88 annualized dividend and a yield of 1.85%. Allergan’s dividend payout ratio is currently 17.61%.
Several equities analysts have commented on AGN shares. Cowen set a $255.00 price target on shares of Allergan and gave the company a “buy” rating in a research report on Monday, April 16th. SunTrust Banks started coverage on shares of Allergan in a research report on Friday, February 23rd. They issued a “buy” rating and a $200.00 price target for the company. They noted that the move was a valuation call. Vetr raised shares of Allergan from a “sell” rating to a “hold” rating and set a $189.60 price target for the company in a research report on Friday, January 26th. Royal Bank of Canada reissued a “buy” rating and issued a $213.00 price target on shares of Allergan in a research report on Wednesday, March 14th. Finally, Morgan Stanley reissued a “buy” rating on shares of Allergan in a research report on Wednesday, January 24th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $214.81.
In other Allergan news, CEO Brent L. Saunders acquired 3,300 shares of the company’s stock in a transaction on Thursday, March 8th. The shares were bought at an average cost of $152.53 per share, for a total transaction of $503,349.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph H. Boccuzi acquired 900 shares of the company’s stock in a transaction on Monday, March 5th. The stock was acquired at an average price of $143.42 per share, for a total transaction of $129,078.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 6,095 shares of company stock worth $936,201 over the last quarter. 0.36% of the stock is owned by company insiders.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.